window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

precision oncology

  • Drug approval,Oncology,Precision medicine,Regulatory Affairs,Respiratory

    NICE recommends amivantamab and lazertinib as first-line option for EGFR-mutated lung cancer

      The National Institute for Health and Care Excellence has [...]

    December 19, 2025
  • Biotech,Cell & Gene Therapy,Clinical Development,Oncology,Precision medicine,Research & Development

    Inaphaea BioLabs boosts precision oncology with new partnerships, advanced tumour models, and digital patient avatars

    Inaphaea BioLabs, the translational contract research organisation (CRO) of ValiRx [...]

    September 26, 2025
  • Artificial Intelligence,Oncology,Precision medicine,Real world evidence,Research & Development,Women in Pharma

    Imagene AI and Sheba Medical Center form alliance to expand precision oncology with real-world data

    Imagene AI has expanded its collaboration with Sheba Medical Center [...]

    September 17, 2025
  • Cell & Gene Therapy,Clinical Development,Clinical Trials,European biotech,Partnerships & Funding,Patient Centricity

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    August 19, 2025
  • Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Precision medicine,Research & Development

    FoRx Therapeutics starts first-in-human trial of novel PARG inhibitor FORX-428 in advanced solid tumors

    FoRx Therapeutics has initiated a first-in-human clinical trial of FORX-428, [...]

    August 11, 2025
  • Artificial Intelligence,Clinical Development,Oncology,Partnerships & Funding,Precision medicine

    One Biosciences raises €15M to advance AI-driven single-cell oncology platform

    One Biosciences, a precision oncology techbio company specialising in clinical-grade [...]

    July 17, 2025
  • Artificial Intelligence,Market Access & Commercialization,Oncology

    Caris CMO on AI, equity, and the future of multi-omic oncology

    The former ASCO president shares his insights on breast cancer [...]

    July 4, 2025
  • Clinical Trials,Patient Centricity,Precision medicine

    Phesi analysis reveals colorectal cancer has highest volume of real-world data — but oncology trials remain outdated

    A new analysis by clinical data analytics firm Phesi reveals [...]

    May 19, 2025
  • Clinical Trials

    ctDNA shown to strongly correlate with treatment outcomes across tumor types, study finds

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top